Clinical trials recruiting for SCLC, Extensive Stage

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
  NCT07508852 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
  NCT07358676 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
  NCT07739758 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  NCT07480213 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy
  NCT07141264 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
  NCT06768307 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
  NCT07625644 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
  NCT07110103 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Lung Cancer Registry
  NCT04654364 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
  NCT05718323 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
  NCT05623319 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
  NCT06243003 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for SCLC, Extensive Stage often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for SCLC, Extensive Stage trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.